Health ❯Healthcare ❯Pharmaceuticals

Drug Development

Clinical Trials Eli Lilly Alzheimer's Disease Obesity Treatments Novo Nordisk Combination Therapy Monoclonal Antibodies Weight Loss Drugs Obesity Treatment Lenacapavir

Padcev and Keytruda Combo Extends Survival in Bladder Cancer Trial

Interim topline results have prompted planned discussions with health authorities for potential regulatory filings.

FDA Approves Brinsupri as First Therapy for Non-Cystic Fibrosis Bronchiectasis

Novartis Ianalumab Meets Efficacy and Safety Goals in Phase 3 Sjögren’s Trials

FDA Grants Accelerated Approval to Zongertinib for HER2-Mutant Lung Cancer

Eli Lilly’s Oral Obesity Pill Triggers Stock Slide After Modest Weight-Loss Results

Optimized Graphene Oxide Nanocarrier Achieves Targeted Tumor Uptake, Paving Way for Theranostics

FDA Approves First Systemic Therapy for H3 K27M-Mutant Diffuse Midline Glioma

Mayo Clinic Administers First U.S. Alpha-Emitter Therapy for Metastatic Breast Cancer

Mounjaro Rivals Trulicity in Cardiovascular Safety and Lowers All-Cause Mortality

GSK Closes $12 Billion Licensing Pact for Hengrui’s COPD Therapy and 11 Preclinical Assets

Merck Launches $3 Billion Cost-Optimization Program Following Q2 Revenue Miss

Celcuity’s Gedatolisib Combos Yield Up to 76% Progression-Free Survival Gain in Phase 3 Trial

EU Backs First Twice-Yearly Injectable for HIV Prevention

EMA Recommends Restricted Approval for Eli Lilly’s Alzheimer’s Drug Kisunla

FDA Rejects Replimune’s RP1 Melanoma Immunotherapy

Cancer Drugs Reverse Alzheimer’s Pathology in Mice, Advance to Clinical Trials

FDA Advisers Recommend Against Approval of GSK’s Myeloma Drug Blenrep

One in Three Infants Received Preventive RSV Antibody in First Season, Study Finds

AstraZeneca’s Baxdrostat Delivers Significant Blood Pressure Reductions in Phase 3 Trial for Resistant Hypertension

Weekly Parkinson’s Injection Secures Patent After Successful Lab Trials